Hims & Hers Health (HIMS) Financials

$28.14 +1.43 (+5.35%)

Closing price 04/24/2025 03:59 PM Eastern

Extended Trading

$27.90 -0.24 (-0.84%)

As of 07:08 AM Eastern

Annual Income Statements for Hims & Hers Health

This table shows Hims & Hers Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-72	-18	-108	-66	-24	126
Consolidated Net Income / (Loss)	-72	-18	-108	-66	-24	126
Net Income / (Loss) Continuing Operations	-72	-18	-108	-66	-24	126
Total Pre-Tax Income	-72	-18	-111	-66	-22	72
Total Operating Income	-74	-15	-115	-69	-29	62
Total Gross Profit	45	109	204	409	715	1,173
Total Revenue	83	149	272	527	872	1,477
Operating Revenue	83	149	272	527	872	1,477
Total Cost of Revenue	38	39	67	118	157	303
Operating Cost of Revenue	38	39	67	118	157	303
Total Operating Expenses	119	125	320	477	744	1,111
Selling, General & Admin Expense	56	26	114	98	130	168
Marketing Expense	63	59	136	273	446	679
Research & Development Expense	-	11	22	29	48	79
Other Operating Expenses / (Income)	-	28	48	77	120	186
Total Other Income / (Expense), net	2.44	-2.84	4.25	2.99	7.88	9.81
Other Income / (Expense), net	2.81	-2.84	4.25	2.99	7.88	9.81
Income Tax Expense	0.09	0.13	-3.14	-0.03	1.98	-54
Basic Earnings per Share	($2.07)	($0.51)	($0.58)	($0.32)	($0.11)	$0.58
Weighted Average Basic Shares Outstanding	34.76M	35.35M	186.78M	204.52M	209.34M	215.94M
Diluted Earnings per Share	($2.07)	($0.51)	($0.58)	($0.32)	($0.11)	$0.53
Weighted Average Diluted Shares Outstanding	34.76M	35.35M	186.78M	204.52M	209.34M	236.81M
Weighted Average Basic & Diluted Shares Outstanding	-	5.03M	205.07M	208.46M	214.25M	222.17M

This table shows Hims & Hers Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-19	-11	-10	-7.16	-7.57	1.25	11	13	76	26
Consolidated Net Income / (Loss)	-19	-11	-10	-7.16	-7.57	1.25	11	13	76	26
Net Income / (Loss) Continuing Operations	-19	-11	-10	-7.16	-7.57	1.25	11	13	76	26
Total Pre-Tax Income	-19	-11	-9.68	-7.17	-6.92	2.20	12	13	24	22
Total Operating Income	-20	-12	-11	-9.24	-8.55	-0.40	9.90	11	22	19
Total Gross Profit	114	132	153	170	187	204	229	257	318	370
Total Revenue	145	167	191	208	227	247	278	316	402	481
Operating Revenue	145	167	191	208	227	247	278	316	402	481
Total Cost of Revenue	30	35	37	38	39	43	49	59	84	112
Operating Cost of Revenue	30	35	37	38	39	43	49	59	84	112
Total Operating Expenses	134	144	165	179	196	204	219	246	296	351
Selling, General & Admin Expense	26	28	31	31	36	32	35	41	45	48
Marketing Expense	78	86	97	107	116	126	131	145	182	221
Research & Development Expense	7.98	8.31	11	12	12	13	15	19	21	24
Other Operating Expenses / (Income)	22	23	26	29	32	33	39	41	48	58
Total Other Income / (Expense), net	1.13	0.58	1.58	2.07	1.64	2.60	2.50	2.39	1.22	3.70
Other Income / (Expense), net	1.13	0.58	1.58	2.07	1.64	2.60	2.50	2.39	1.22	3.70
Income Tax Expense	-0.02	-0.12	0.39	-0.01	0.65	0.95	1.28	0.13	-52	-3.73
Basic Earnings per Share	($0.09)	($0.05)	($0.05)	($0.03)	($0.04)	$0.01	$0.05	$0.06	$0.35	$0.12
Weighted Average Basic Shares Outstanding	205.23M	204.52M	207.14M	208.42M	210.13M	209.34M	213.45M	214.62M	216.62M	215.94M
Diluted Earnings per Share	($0.09)	($0.05)	($0.05)	($0.03)	($0.04)	$0.01	$0.05	$0.06	$0.32	$0.10
Weighted Average Diluted Shares Outstanding	205.23M	204.52M	207.14M	208.42M	210.13M	209.34M	229.36M	234.79M	235.07M	236.81M
Weighted Average Basic & Diluted Shares Outstanding	207.74M	208.46M	209.32M	211.02M	211.99M	214.25M	214.79M	217.08M	218.48M	222.17M

This table details how cash moves in and out of Hims & Hers Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	-19	5.55	44	-25	50	124
Net Cash From Operating Activities	-75	-2.48	-34	-27	73	251
Net Cash From Continuing Operating Activities	-75	-2.48	-34	-27	73	251
Net Income / (Loss) Continuing Operations	-72	-18	-108	-66	-24	126
Consolidated Net Income / (Loss)	-72	-18	-108	-66	-24	126
Depreciation Expense	0.26	1.06	4.08	7.47	9.52	17
Amortization Expense	-0.13	0.65	2.31	0.15	-5.69	-4.36
Non-Cash Adjustments To Reconcile Net Income	6.92	9.75	67	36	72	93
Changes in Operating Assets and Liabilities, net	-9.85	4.19	0.07	-4.61	21	20
Net Cash From Investing Activities	-39	-40	-156	35	-12	-19
Net Cash From Continuing Investing Activities	-39	-40	-156	35	-12	-19
Purchase of Property, Plant & Equipment	-1.79	-4.23	-5.01	-7.25	-26	-53
Acquisitions	0.00	0.00	-46	-0.46	0.00	-15
Purchase of Investments	-42	-95	-267	-188	-157	-161
Sale and/or Maturity of Investments	4.50	60	162	230	172	210
Net Cash From Financing Activities	95	48	235	-33	-11	-108
Net Cash From Continuing Financing Activities	95	48	235	-33	-11	-108
Repurchase of Common Equity	0.00	-3.36	-35	0.00	-2.00	-83
Issuance of Common Equity	0.00	0.00	75	1.18	2.30	3.90
Other Financing Activities, net	0.04	0.68	194	-34	-12	-29
Effect of Exchange Rate Changes	-0.01	-0.01	-0.07	-0.05	-0.01	-0.27
Cash Income Taxes Paid	0.14	0.22	0.34	0.64	1.11	7.92

This table details how cash moves in and out of Hims & Hers Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	2.93	-11	1.97	17	-7.42	39	8.57	24	36	55
Net Cash From Operating Activities	5.99	-6.72	9.48	17	25	22	26	54	85	86
Net Cash From Continuing Operating Activities	5.99	-6.72	9.48	17	25	22	26	54	85	86
Net Income / (Loss) Continuing Operations	-19	-11	-10	-7.16	-7.57	1.25	11	13	76	26
Consolidated Net Income / (Loss)	-19	-11	-10	-7.16	-7.57	1.25	11	13	76	26
Depreciation Expense	1.90	2.01	2.12	2.38	2.36	2.66	3.00	3.64	4.38	6.06
Amortization Expense	0.12	-0.84	-1.04	-1.48	-1.52	-1.65	-1.08	-1.20	-1.16	-0.92
Non-Cash Adjustments To Reconcile Net Income	12	11	16	18	20	19	20	22	26	25
Changes in Operating Assets and Liabilities, net	11	-8.42	2.45	5.17	12	0.88	-7.30	16	-19	30
Net Cash From Investing Activities	-2.58	6.00	-4.11	2.37	-31	21	13	-4.47	-10	-17
Net Cash From Continuing Investing Activities	-2.58	6.00	-4.11	2.37	-31	21	13	-4.47	-10	-17
Purchase of Property, Plant & Equipment	-1.96	-2.61	-2.51	-6.86	-5.92	-11	-14	-6.03	-5.88	-27
Purchase of Investments	-48	-51	-41	-25	-71	-21	-71	-27	-53	-9.97
Sale and/or Maturity of Investments	47	60	39	34	46	53	98	28	64	20
Net Cash From Financing Activities	-0.49	-10	-3.41	-2.54	-1.56	-3.96	-30	-25	-39	-14
Net Cash From Continuing Financing Activities	-0.49	-10	-3.41	-2.54	-1.56	-3.96	-30	-25	-39	-14
Repurchase of Common Equity	-	-	0.00	-	-	-2.00	-28	-20	-30	-5.01
Issuance of Common Equity	-	0.63	-	-	-	1.40	-	-	-	2.28
Other Financing Activities, net	-0.49	-11	-3.41	-3.44	-1.56	-3.36	-2.24	-6.76	-8.78	-11
Effect of Exchange Rate Changes	0.02	-0.02	0.02	0.01	0.01	-0.05	0.00	-0.00	0.19	-0.46
Cash Income Taxes Paid	0.06	0.05	0.29	0.34	0.02	0.46	0.13	3.34	0.40	4.04

This table presents Hims & Hers Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024
Total Assets	205	119	421	366	441	708
Total Current Assets	1.66	113	270	217	265	396
Cash & Equivalents	1.51	27	72	47	97	221
Short-Term Investments	-	73	175	133	124	80
Inventories, net	-	3.54	14	22	22	64
Prepaid Expenses	0.15	5.40	9.07	15	22	31
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	203	5.61	151	150	176	312
Goodwill	-	0.00	111	111	111	113
Intangible Assets	-	0.06	26	22	19	43
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	0.00	62
Other Noncurrent Operating Assets	203	5.55	14	17	47	94
Total Liabilities & Shareholders' Equity	205	119	421	366	441	708
Total Liabilities	8.17	16	86	55	97	231
Total Current Liabilities	0.98	15	79	48	88	221
Short-Term Debt	-	0.00	43	0.00	7.41	0.00
Accounts Payable	0.45	8.07	20	32	43	91
Accrued Expenses	0.53	4.98	12	12	29	53
Current Deferred Revenue	-	1.27	3.19	1.47	7.73	75
Other Current Liabilities	-	0.91	1.37	1.66	1.28	1.89
Total Noncurrent Liabilities	7.19	0.38	6.75	6.66	8.69	9.46
Other Noncurrent Operating Liabilities	7.19	0.38	6.75	6.66	8.69	9.46
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	5.00	-147	335	312	344	477
Total Preferred & Common Equity	5.00	-147	335	312	344	477
Total Common Equity	5.00	-147	335	312	344	477
Common Stock	3.85	24	614	657	712	719
Retained Earnings	1.15	-171	-279	-345	-368	-242
Accumulated Other Comprehensive Income / (Loss)	-	-0.01	-0.14	-0.28	-0.12	-0.32

This table presents Hims & Hers Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	383	376	390	414	448	481	602
Total Current Assets	233	226	235	250	262	291	326
Cash & Equivalents	58	49	65	58	105	129	166
Short-Term Investments	140	136	128	155	98	98	89
Inventories, net	22	21	21	22	30	41	49
Prepaid Expenses	13	20	20	16	28	23	23
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	149	151	155	164	186	190	276
Goodwill	111	111	111	111	111	111	113
Intangible Assets	22	21	20	19	18	17	45
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	-	54
Other Noncurrent Operating Assets	16	19	24	33	58	62	64
Total Liabilities & Shareholders' Equity	383	376	390	414	448	481	602
Total Liabilities	72	64	70	85	104	119	162
Total Current Liabilities	67	56	67	83	93	109	153
Short-Term Debt	13	-	4.78	6.86	7.41	0.00	0.00
Accounts Payable	33	38	38	42	44	57	75
Accrued Expenses	17	14	20	27	27	29	43
Current Deferred Revenue	2.12	2.87	2.06	4.39	14	21	32
Other Current Liabilities	1.61	1.69	1.84	1.93	1.54	1.63	1.79
Total Noncurrent Liabilities	5.06	7.28	3.27	2.76	10	9.86	9.57
Other Noncurrent Operating Liabilities	5.06	7.28	3.27	2.76	10	9.86	9.57
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	311	313	320	329	344	362	440
Total Preferred & Common Equity	311	313	320	329	344	362	440
Total Common Equity	311	313	320	329	344	362	440
Common Stock	645	668	682	698	702	706	708
Retained Earnings	-334	-355	-362	-369	-357	-344	-268
Accumulated Other Comprehensive Income / (Loss)	-0.46	-0.11	-0.26	-0.13	-0.16	-0.17	0.23

This table displays calculated financial ratios and metrics derived from Hims & Hers Health's official financial filings.

Metric	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	80.18%	82.77%	93.81%	65.49%	69.33%
EBITDA Growth	0.00%	77.22%	-541.22%	44.36%	69.46%	575.96%
EBIT Growth	0.00%	74.88%	-515.97%	40.69%	67.17%	432.44%
NOPAT Growth	0.00%	79.65%	-659.65%	40.29%	57.13%	627.72%
Net Income Growth	0.00%	74.86%	-494.34%	38.99%	64.15%	635.28%
EPS Growth	0.00%	75.36%	-13.73%	44.83%	65.63%	581.82%
Operating Cash Flow Growth	0.00%	96.69%	-1,288.14%	22.90%	376.97%	241.69%
Free Cash Flow Firm Growth	0.00%	0.00%	-214.44%	75.93%	62.10%	431.18%
Invested Capital Growth	0.00%	-98.52%	4,420.10%	1.49%	-1.25%	35.26%
Revenue Q/Q Growth	0.00%	0.00%	18.91%	18.56%	10.02%	18.88%
EBITDA Q/Q Growth	0.00%	0.00%	-31.04%	24.96%	42.53%	40.25%
EBIT Q/Q Growth	0.00%	0.00%	-30.71%	23.53%	38.13%	38.93%
NOPAT Q/Q Growth	0.00%	0.00%	-17.27%	12.66%	27.56%	29.26%
Net Income Q/Q Growth	0.00%	0.00%	-31.73%	23.57%	34.04%	24.47%
EPS Q/Q Growth	0.00%	0.00%	6.45%	15.79%	35.29%	20.45%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-8.98%	-15.77%	64.09%	34.50%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	8.47%	26.68%	197.32%
Invested Capital Q/Q Growth	0.00%	0.00%	3.37%	5.25%	6.13%	-5.12%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	54.03%	73.58%	75.22%	77.57%	81.99%	79.45%
EBITDA Margin	-86.58%	-10.95%	-38.40%	-11.02%	-2.03%	5.72%
Operating Margin	-90.14%	-10.18%	-42.31%	-13.04%	-3.38%	4.19%
EBIT Margin	-86.73%	-12.09%	-40.75%	-12.47%	-2.47%	4.86%
Profit (Net Income) Margin	-87.29%	-12.18%	-39.60%	-12.46%	-2.70%	8.54%
Tax Burden Percent	100.13%	100.71%	97.17%	99.95%	109.16%	175.76%
Interest Burden Percent	100.52%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	-75.76%
Return on Invested Capital (ROIC)	-26.70%	-10.71%	-121.04%	-36.67%	-15.70%	70.90%
ROIC Less NNEP Spread (ROIC-NNEP)	1,295.79%	4.06%	-103.23%	-27.51%	-14.21%	64.19%
Return on Net Nonoperating Assets (RNNOA)	-9.96%	-1.38%	71.85%	16.34%	8.52%	-40.18%
Return on Equity (ROE)	-36.66%	-12.09%	-49.19%	-20.32%	-7.18%	30.71%
Cash Return on Invested Capital (CROIC)	0.00%	183.47%	-312.39%	-38.14%	-14.44%	40.92%
Operating Return on Assets (OROA)	-34.97%	-11.12%	-41.09%	-16.70%	-5.34%	12.49%
Return on Assets (ROA)	-35.19%	-11.20%	-39.93%	-16.69%	-5.83%	21.94%
Return on Common Equity (ROCE)	-0.93%	5.72%	-21.10%	-20.32%	-7.18%	30.71%
Return on Equity Simple (ROE_SIMPLE)	-1,441.28%	12.33%	-32.17%	-21.07%	-6.84%	26.44%
Net Operating Profit after Tax (NOPAT)	-52	-11	-81	-48	-21	109
NOPAT Margin	-63.09%	-7.13%	-29.62%	-9.13%	-2.36%	7.37%
Net Nonoperating Expense Percent (NNEP)	-1,322.50%	-14.77%	-17.81%	-9.16%	-1.49%	6.71%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-15.43%	-5.87%	22.82%
Cost of Revenue to Revenue	45.97%	26.42%	24.78%	22.43%	18.01%	20.55%
SG&A Expenses to Revenue	67.67%	17.50%	41.81%	18.64%	14.89%	11.36%
R&D to Revenue	0.00%	7.55%	8.23%	5.55%	5.53%	5.34%
Operating Expenses to Revenue	144.16%	83.76%	117.53%	90.61%	85.37%	75.26%
Earnings before Interest and Taxes (EBIT)	-72	-18	-111	-66	-22	72
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-71	-16	-104	-58	-18	84
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	49.81	0.00	3.99	4.27	5.48	11.08
Price to Tangible Book Value (P/TBV)	49.81	0.00	6.75	7.44	8.79	16.48
Price to Revenue (P/Rev)	3.02	2.47	4.91	2.53	2.16	3.58
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	41.91
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	2.39%
Enterprise Value to Invested Capital (EV/IC)	2.25	179.53	8.69	8.72	12.83	28.24
Enterprise Value to Revenue (EV/Rev)	5.32	3.48	4.16	2.19	1.92	3.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	59.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	69.48
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	45.80
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	22.77	19.84
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	2.85	0.00	0.00	0.00	79.35
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.13	0.00	0.02	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.01	-0.34	-0.70	-0.59	-0.60	-0.63
Leverage Ratio	1.04	1.08	1.23	1.22	1.23	1.40
Compound Leverage Factor	1.05	1.08	1.23	1.22	1.23	1.40
Debt to Total Capital	0.00%	0.00%	11.35%	0.00%	2.11%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	11.35%	0.00%	2.11%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	97.46%	242.47%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	2.54%	-142.47%	88.65%	100.00%	97.89%	100.00%
Debt to EBITDA	0.00	0.00	-0.41	0.00	-0.42	0.00
Net Debt to EBITDA	0.00	0.00	1.96	0.00	12.04	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	-0.53	0.00	-0.36	0.00
Net Debt to NOPAT	0.00	0.00	2.54	0.00	10.36	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	17.54	13.84	8.71	14.71	12.78	15.97
Noncontrolling Interest Sharing Ratio	97.46%	147.34%	57.11%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	1.69	7.43	3.41	4.52	3.00	1.79
Quick Ratio	1.54	6.58	3.12	3.75	2.50	1.36
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	182	-208	-50	-19	63
Operating Cash Flow to CapEx	-4,189.54%	-58.56%	-687.28%	-366.10%	277.38%	475.99%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-202.89	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-207.73	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.40	0.92	1.01	1.34	2.16	2.57
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	7.88	6.73	7.13	6.98
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	85.10	9.24	4.86	4.55	4.16	4.52
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	46.32	54.23	51.16	52.27
Days Payable Outstanding (DPO)	4.29	39.52	75.04	80.30	87.66	80.76
Cash Conversion Cycle (CCC)	-4.29	-39.52	-28.72	-26.07	-36.50	-28.49
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	195	2.88	130	132	130	176
Invested Capital Turnover	0.42	1.50	4.09	4.02	6.64	9.62
Increase / (Decrease) in Invested Capital	0.00	-192	127	1.94	-1.66	46
Enterprise Value (EV)	439	517	1,131	1,152	1,673	4,983
Market Capitalization	249	367	1,336	1,332	1,887	5,283
Book Value per Share	$0.20	($5.84)	$1.64	$1.50	$1.62	$2.18
Tangible Book Value per Share	$0.20	($5.84)	$0.97	$0.86	$1.01	$1.47
Total Capital	197	103	377	312	351	477
Total Debt	0.00	0.00	43	0.00	7.41	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-1.51	-100	-204	-180	-214	-300
Capital Expenditures (CapEx)	1.79	4.23	5.01	7.25	26	53
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.83	-2.35	-14	-11	-37	-126
Debt-free Net Working Capital (DFNWC)	0.68	98	234	169	184	174
Net Working Capital (NWC)	0.68	98	191	169	177	174
Net Nonoperating Expense (NNE)	20	7.51	27	18	2.93	-17
Net Nonoperating Obligations (NNO)	-1.51	-100	-204	-180	-214	-300
Total Depreciation and Amortization (D&A)	0.13	1.70	6.39	7.62	3.83	13
Debt-free, Cash-free Net Working Capital to Revenue	-1.01%	-1.58%	-5.06%	-2.08%	-4.24%	-8.52%
Debt-free Net Working Capital to Revenue	0.82%	65.78%	85.89%	32.01%	21.10%	11.82%
Net Working Capital to Revenue	0.82%	65.78%	70.14%	32.01%	20.25%	11.82%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.96)	($0.58)	($0.32)	($0.11)	$0.58
Adjusted Weighted Average Basic Shares Outstanding	0.00	191.35M	186.78M	204.52M	209.34M	215.94M
Adjusted Diluted Earnings per Share	$0.00	($0.96)	($0.58)	($0.32)	($0.11)	$0.53
Adjusted Weighted Average Diluted Shares Outstanding	0.00	191.35M	186.78M	204.52M	209.34M	236.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.96)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	25.16M	205.07M	208.46M	214.25M	222.17M
Normalized Net Operating Profit after Tax (NOPAT)	-52	-11	-81	-48	-21	43
Normalized NOPAT Margin	-63.09%	-7.13%	-29.62%	-9.13%	-2.36%	2.93%
Pre Tax Income Margin	-87.18%	-12.09%	-40.75%	-12.47%	-2.47%	4.86%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-194.05	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-141.16	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-198.89	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-146.01	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-18.53%	-32.40%	0.00%	-8.49%	65.88%

This table displays calculated financial ratios and metrics derived from Hims & Hers Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	95.27%	97.41%	88.30%	83.08%	56.52%	47.50%	45.81%	51.82%	77.13%	95.09%
EBITDA Growth	-2.65%	66.22%	36.00%	65.08%	63.94%	132.48%	266.50%	353.04%	541.80%	756.87%
EBIT Growth	1.35%	64.71%	40.09%	63.54%	63.32%	119.91%	228.12%	287.22%	441.14%	915.07%
NOPAT Growth	27.76%	46.19%	33.43%	54.25%	57.19%	97.21%	212.70%	268.99%	1,297.14%	9,673.78%
Net Income Growth	-18.19%	65.00%	38.06%	63.63%	59.84%	111.41%	210.54%	285.79%	1,098.92%	1,990.36%
EPS Growth	-12.50%	54.55%	37.50%	70.00%	55.56%	120.00%	200.00%	300.00%	900.00%	900.00%
Operating Cash Flow Growth	137.50%	-116.39%	148.87%	363.15%	320.90%	427.18%	172.47%	218.52%	238.48%	292.96%
Free Cash Flow Firm Growth	-127.70%	92.93%	100.78%	99.36%	75.06%	114.21%	-891.54%	812.83%	354.72%	-1,799.80%
Invested Capital Growth	-0.32%	1.49%	-6.74%	-3.90%	-2.07%	-1.25%	15.54%	2.25%	51.29%	35.26%
Revenue Q/Q Growth	27.54%	15.44%	14.09%	8.99%	9.04%	8.79%	12.79%	13.47%	27.22%	19.82%
EBITDA Q/Q Growth	6.25%	41.43%	13.33%	27.15%	3.17%	152.75%	347.44%	10.72%	69.05%	2.31%
EBIT Q/Q Growth	4.12%	41.51%	12.77%	25.94%	3.54%	131.75%	464.80%	8.23%	75.75%	-5.52%
NOPAT Q/Q Growth	1.03%	41.93%	2.95%	18.00%	7.38%	96.21%	4,017.96%	22.97%	556.09%	-69.71%
Net Income Q/Q Growth	4.26%	42.11%	7.70%	28.91%	-5.73%	116.45%	793.82%	19.49%	468.46%	-65.57%
EPS Q/Q Growth	10.00%	44.44%	0.00%	40.00%	-33.33%	125.00%	400.00%	20.00%	433.33%	-68.75%
Operating Cash Flow Q/Q Growth	193.60%	-212.26%	241.14%	77.43%	49.71%	-12.73%	17.54%	107.42%	59.10%	1.31%
Free Cash Flow Firm Q/Q Growth	92.26%	25.93%	113.89%	-179.85%	-203.51%	142.19%	-874.20%	171.91%	8.46%	-381.52%
Invested Capital Q/Q Growth	-8.41%	5.25%	-2.85%	2.61%	-6.66%	6.13%	13.68%	-9.19%	38.10%	-5.12%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	79.02%	79.15%	80.42%	81.84%	82.62%	82.74%	82.36%	81.30%	79.16%	76.81%
EBITDA Margin	-11.62%	-5.90%	-4.51%	-3.02%	-2.68%	1.30%	5.15%	5.03%	6.68%	5.70%
Operating Margin	-13.80%	-6.94%	-5.90%	-4.44%	-3.77%	-0.16%	3.56%	3.49%	5.57%	3.87%
EBIT Margin	-13.02%	-6.60%	-5.07%	-3.45%	-3.05%	0.89%	4.46%	4.25%	5.88%	4.63%
Profit (Net Income) Margin	-13.01%	-6.52%	-5.28%	-3.44%	-3.34%	0.50%	4.00%	4.21%	18.82%	5.41%
Tax Burden Percent	99.92%	98.90%	103.99%	99.82%	109.41%	56.69%	89.72%	99.05%	320.38%	116.75%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	43.31%	10.28%	0.95%	-220.38%	-16.75%
Return on Invested Capital (ROIC)	-34.14%	-19.52%	-19.15%	-16.45%	-16.85%	-0.61%	22.15%	27.73%	143.55%	43.42%
ROIC Less NNEP Spread (ROIC-NNEP)	-31.80%	-18.07%	-17.99%	-16.07%	-16.04%	-1.36%	20.97%	26.59%	141.85%	41.74%
Return on Net Nonoperating Assets (RNNOA)	19.79%	10.74%	10.52%	9.31%	9.81%	0.82%	-12.15%	-16.21%	-84.84%	-26.13%
Return on Equity (ROE)	-14.34%	-8.78%	-8.64%	-7.13%	-7.04%	0.20%	10.01%	11.53%	58.71%	17.29%
Cash Return on Invested Capital (CROIC)	-43.47%	-38.14%	-26.20%	-23.15%	-20.82%	-14.44%	13.03%	5.48%	13.67%	40.92%
Operating Return on Assets (OROA)	-14.41%	-8.83%	-8.25%	-6.37%	-6.07%	1.92%	10.38%	10.43%	14.36%	11.91%
Return on Assets (ROA)	-14.40%	-8.74%	-8.58%	-6.36%	-6.64%	1.09%	9.31%	10.33%	46.02%	13.91%
Return on Common Equity (ROCE)	-14.34%	-8.78%	-8.64%	-7.13%	-7.04%	0.20%	10.01%	11.53%	58.71%	17.29%
Return on Equity Simple (ROE_SIMPLE)	-27.64%	0.00%	-19.02%	-14.68%	-10.86%	0.00%	-0.68%	5.00%	23.01%	0.00%
Net Operating Profit after Tax (NOPAT)	-14	-8.12	-7.88	-6.47	-5.99	-0.23	8.88	11	72	22
NOPAT Margin	-9.66%	-4.86%	-4.13%	-3.11%	-2.64%	-0.09%	3.19%	3.46%	17.85%	4.51%
Net Nonoperating Expense Percent (NNEP)	-2.34%	-1.45%	-1.17%	-0.37%	-0.81%	0.75%	1.18%	1.14%	1.70%	1.68%
Return On Investment Capital (ROIC_SIMPLE)	-	-2.61%	-	-	-	-0.06%	-	-	-	4.55%
Cost of Revenue to Revenue	20.98%	20.85%	19.58%	18.16%	17.38%	17.26%	17.64%	18.70%	20.84%	23.19%
SG&A Expenses to Revenue	18.12%	16.49%	15.99%	14.98%	15.84%	13.10%	12.43%	12.85%	11.11%	9.98%
R&D to Revenue	5.51%	4.97%	5.63%	5.68%	5.41%	5.44%	5.51%	5.91%	5.25%	4.94%
Operating Expenses to Revenue	92.82%	86.09%	86.33%	86.28%	86.40%	82.90%	78.80%	77.80%	73.59%	72.94%
Earnings before Interest and Taxes (EBIT)	-19	-11	-9.68	-7.17	-6.92	2.20	12	13	24	22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-17	-9.86	-8.61	-6.27	-6.07	3.20	14	16	27	27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.72	4.27	6.61	6.15	4.04	5.48	9.52	11.98	9.09	11.08
Price to Tangible Book Value (P/TBV)	6.49	7.44	11.43	10.40	6.69	8.79	15.20	18.54	14.15	16.48
Price to Revenue (P/Rev)	2.60	2.53	3.36	2.77	1.67	2.16	3.42	4.06	3.22	3.58
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	240.13	39.51	41.91
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.42%	2.53%	2.39%
Enterprise Value to Invested Capital (EV/IC)	7.73	8.72	14.67	13.51	9.12	12.83	20.79	30.51	20.13	28.24
Enterprise Value to Revenue (EV/Rev)	2.18	2.19	3.06	2.50	1.42	1.92	3.21	3.85	3.01	3.37
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	594.10	150.40	62.19	59.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	6,010.45	194.69	72.55	69.48
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	81.19	399.96	44.49	45.80
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	799.80	69.57	25.05	22.77	34.32	32.46	20.06	19.84
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	171.03	562.52	177.30	79.35
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.04	0.00	0.00	0.01	0.02	0.02	0.02	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.62	-0.59	-0.58	-0.58	-0.61	-0.60	-0.58	-0.61	-0.60	-0.63
Leverage Ratio	1.21	1.22	1.18	1.20	1.25	1.23	1.25	1.28	1.32	1.40
Compound Leverage Factor	1.21	1.22	1.18	1.20	1.25	1.23	1.25	1.28	1.32	1.40
Debt to Total Capital	4.00%	0.00%	0.00%	1.47%	2.05%	2.11%	2.11%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	4.00%	0.00%	0.00%	1.47%	2.05%	2.11%	2.11%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	96.00%	100.00%	100.00%	98.53%	97.95%	97.89%	97.89%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.17	0.00	0.00	-0.11	-0.22	-0.42	1.43	0.00	0.00	0.00
Net Debt to EBITDA	2.40	0.00	0.00	4.52	6.66	12.04	-37.80	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.24	0.00	0.00	-0.13	-0.24	-0.36	0.20	0.00	0.00	0.00
Net Debt to NOPAT	3.37	0.00	0.00	5.17	7.23	10.36	-5.17	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	9.95	15.21	20.29	17.89	10.43	12.96	20.56	23.72	16.70	15.74
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.49	4.52	4.01	3.53	3.03	3.00	2.80	2.68	2.14	1.79
Quick Ratio	2.97	3.75	3.28	2.90	2.57	2.50	2.18	2.09	1.66	1.36
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-14	-10	1.40	-1.12	-3.39	1.43	-11	7.96	8.63	-24
Operating Cash Flow to CapEx	305.20%	-257.14%	377.81%	245.13%	425.52%	196.31%	185.11%	889.38%	1,449.87%	321.31%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.11	1.34	1.63	1.85	1.99	2.16	2.33	2.45	2.44	2.57
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	6.38	6.73	7.86	6.83	6.74	7.13	6.68	6.13	6.59	6.98
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	4.32	4.55	4.19	4.29	3.98	4.16	4.14	3.99	3.99	4.52
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	57.21	54.23	46.47	53.43	54.18	51.16	54.63	59.54	55.37	52.27
Days Payable Outstanding (DPO)	84.53	80.30	87.04	84.99	91.61	87.66	88.15	91.57	91.46	80.76
Cash Conversion Cycle (CCC)	-27.33	-26.07	-40.57	-31.56	-37.43	-36.50	-33.53	-32.03	-36.09	-28.49
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	126	132	128	132	123	130	148	135	186	176
Invested Capital Turnover	3.53	4.02	4.63	5.29	6.38	6.64	6.94	8.01	8.04	9.62
Increase / (Decrease) in Invested Capital	-0.41	1.94	-9.28	-5.35	-2.60	-1.66	20	2.97	63	46
Enterprise Value (EV)	970	1,152	1,884	1,779	1,122	1,673	3,083	4,109	3,745	4,983
Market Capitalization	1,156	1,332	2,068	1,968	1,327	1,887	3,280	4,337	3,999	5,283
Book Value per Share	$1.50	$1.50	$1.50	$1.53	$1.56	$1.62	$1.61	$1.69	$2.03	$2.18
Tangible Book Value per Share	$0.86	$0.86	$0.87	$0.90	$0.94	$1.01	$1.01	$1.09	$1.30	$1.47
Total Capital	324	312	313	325	335	351	352	362	440	477
Total Debt	13	0.00	0.00	4.78	6.86	7.41	7.41	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-185	-180	-184	-188	-206	-214	-196	-227	-254	-300
Capital Expenditures (CapEx)	1.96	2.61	2.51	6.86	5.92	11	14	6.03	5.88	27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-19	-11	-15	-20	-38	-37	-28	-45	-80	-126
Debt-free Net Working Capital (DFNWC)	180	169	169	173	175	184	176	182	174	174
Net Working Capital (NWC)	167	169	169	168	168	177	168	182	174	174
Net Nonoperating Expense (NNE)	4.85	2.78	2.18	0.69	1.58	-1.47	-2.24	-2.37	-3.91	-4.31
Net Nonoperating Obligations (NNO)	-185	-180	-184	-188	-206	-214	-196	-227	-254	-300
Total Depreciation and Amortization (D&A)	2.03	1.17	1.08	0.90	0.85	1.01	1.92	2.44	3.22	5.15
Debt-free, Cash-free Net Working Capital to Revenue	-4.23%	-2.08%	-2.46%	-2.85%	-4.79%	-4.24%	-2.89%	-4.22%	-6.47%	-8.52%
Debt-free Net Working Capital to Revenue	40.42%	32.01%	27.46%	24.32%	22.02%	21.10%	18.33%	17.08%	13.99%	11.82%
Net Working Capital to Revenue	37.50%	32.01%	27.46%	23.65%	21.16%	20.25%	17.55%	17.08%	13.99%	11.82%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.09)	($0.05)	($0.05)	($0.03)	($0.04)	$0.01	$0.05	$0.06	$0.35	$0.12
Adjusted Weighted Average Basic Shares Outstanding	205.23M	204.52M	207.14M	208.42M	210.13M	209.34M	213.45M	214.62M	216.62M	215.94M
Adjusted Diluted Earnings per Share	($0.09)	($0.05)	($0.05)	($0.03)	($0.04)	$0.01	$0.05	$0.06	$0.32	$0.10
Adjusted Weighted Average Diluted Shares Outstanding	205.23M	204.52M	207.14M	208.42M	210.13M	209.34M	229.36M	234.79M	235.07M	236.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	207.74M	208.46M	209.32M	211.02M	211.99M	214.25M	214.79M	217.08M	218.48M	222.17M
Normalized Net Operating Profit after Tax (NOPAT)	-14	-8.12	-7.88	-6.47	-5.99	-0.23	8.88	11	16	13
Normalized NOPAT Margin	-9.66%	-4.86%	-4.13%	-3.11%	-2.64%	-0.09%	3.19%	3.46%	3.90%	2.71%
Pre Tax Income Margin	-13.02%	-6.60%	-5.07%	-3.45%	-3.05%	0.89%	4.46%	4.25%	5.88%	4.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-8.49%	-1,278.73%	276.17%	79.04%	65.88%

Frequently Asked Questions About Hims & Hers Health's Financials

When does Hims & Hers Health's fiscal year end?

According to the most recent income statement we have on file, Hims & Hers Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Hims & Hers Health's net income changed over the last 5 years?

Hims & Hers Health's net income appears to be on a downward trend, with a most recent value of $126.04 million in 2024, falling from -$72.06 million in 2019. The previous period was -$23.55 million in 2023.

What is Hims & Hers Health's operating income?

Hims & Hers Health's total operating income in 2024 was $61.90 million, based on the following breakdown:

Total Gross Profit: $1.17 billion
Total Operating Expenses: $1.11 billion

How has Hims & Hers Health revenue changed over the last 5 years?

Over the last 5 years, Hims & Hers Health's total revenue changed from $82.56 million in 2019 to $1.48 billion in 2024, a change of 1,688.5%.

How much debt does Hims & Hers Health have?

Hims & Hers Health's total liabilities were at $230.82 million at the end of 2024, a 137.6% increase from 2023, and a 2,724.2% increase since 2019.

How much cash does Hims & Hers Health have?

In the past 5 years, Hims & Hers Health's cash and equivalents has ranged from $1.51 million in 2019 to $220.58 million in 2024, and is currently $220.58 million as of their latest financial filing in 2024.

How has Hims & Hers Health's book value per share changed over the last 5 years?

Over the last 5 years, Hims & Hers Health's book value per share changed from 0.20 in 2019 to 2.18 in 2024, a change of 997.6%.

Related Companies

This page (NYSE:HIMS) was last updated on 4/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hims & Hers Health (HIMS) Financials

Frequently Asked Questions About Hims & Hers Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hims & Hers Health (HIMS) Financials

Annual Income Statements for Hims & Hers Health

Quarterly Income Statements for Hims & Hers Health

Annual Cash Flow Statements for Hims & Hers Health

Quarterly Cash Flow Statements for Hims & Hers Health

Annual Balance Sheets for Hims & Hers Health

Quarterly Balance Sheets for Hims & Hers Health

Annual Metrics and Ratios for Hims & Hers Health

Quarterly Metrics and Ratios for Hims & Hers Health

Frequently Asked Questions About Hims & Hers Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools